TY - JOUR
T1 - Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
AU - Harrison, Stephen A.
AU - Ratziu, Vlad
AU - Anstee, Quentin M.
AU - Noureddin, Mazen
AU - Sanyal, Arun J.
AU - Schattenberg, Jörn M.
AU - Bedossa, Pierre
AU - Bashir, Mustafa R.
AU - Schneider, David
AU - Taub, Rebecca
AU - Bansal, Meena
AU - Kowdley, Kris V.
AU - Younossi, Zobair M
AU - Loomba, Rohit
N1 - Funding Information:
Declaration of personal interests: The Phase 3 MAESTRO clinical programme is sponsored/funded by Madrigal Pharmaceuticals. Medical writing and editorial assistance were provided by Theresa Alexander, PhD, Karen Finnegan, PhD, Barton F. Isaac, PharmD, and Peter Rydqvist, PharmD, all employees of Madrigal Pharmaceuticals. QMA is supported by the Newcastle NIHR Biomedical Research Centre.
Funding Information:
: The Phase 3 MAESTRO clinical programme is sponsored/funded by Madrigal Pharmaceuticals. Medical writing and editorial assistance were provided by Theresa Alexander, PhD, Karen Finnegan, PhD, Barton F. Isaac, PharmD, and Peter Rydqvist, PharmD, all employees of Madrigal Pharmaceuticals. QMA is supported by the Newcastle NIHR Biomedical Research Centre. Declaration of personal interests
Publisher Copyright:
© 2023 Madrigal Pharmaceuticals. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - Background: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver-targeted thyroid hormone receptor-β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo. Aims: To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO-NAFLD-1 [NCT04197479], MAESTRO-NAFLD-OLE [NCT04951219], MAESTRO-NASH [NCT03900429], MAESTRO-NASH-OUTCOMES [NCT05500222]). Methods: MAESTRO-NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy-confirmed at-risk NASH. Patients are randomised to a once-daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO-NAFLD-1 is a 52-week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non-invasive testing); ~700 patients from MAESTRO-NAFLD-1 are enrolled in MAESTRO-NAFLD-OLE, a 52-week active treatment extension to further evaluate safety. MAESTRO-NASH-OUTCOMES is enrolling 700 adults with well-compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non-invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient-reported outcomes. Conclusion: The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long-term clinical liver-related outcomes in MAESTRO-NASH (month 54) and MAESTRO-NASH-OUTCOMES (time to event).
AB - Background: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver-targeted thyroid hormone receptor-β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo. Aims: To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO-NAFLD-1 [NCT04197479], MAESTRO-NAFLD-OLE [NCT04951219], MAESTRO-NASH [NCT03900429], MAESTRO-NASH-OUTCOMES [NCT05500222]). Methods: MAESTRO-NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy-confirmed at-risk NASH. Patients are randomised to a once-daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO-NAFLD-1 is a 52-week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non-invasive testing); ~700 patients from MAESTRO-NAFLD-1 are enrolled in MAESTRO-NAFLD-OLE, a 52-week active treatment extension to further evaluate safety. MAESTRO-NASH-OUTCOMES is enrolling 700 adults with well-compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non-invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient-reported outcomes. Conclusion: The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long-term clinical liver-related outcomes in MAESTRO-NASH (month 54) and MAESTRO-NASH-OUTCOMES (time to event).
KW - Adult
KW - Humans
KW - Non-alcoholic Fatty Liver Disease/pathology
KW - Liver/pathology
KW - Liver Cirrhosis/complications
KW - Biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85173514055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173514055&partnerID=8YFLogxK
U2 - 10.1111/apt.17734
DO - 10.1111/apt.17734
M3 - Article
C2 - 37786277
AN - SCOPUS:85173514055
SN - 0269-2813
VL - 59
SP - 51
EP - 63
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 1
ER -